.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

SERDs in Focus: Optimizing Treatment Strategies in HR+ HER2- Breast Cancer

Expert discussions on the latest advances in biomarker testing, endocrine resistance, and treatment sequencing with oral SERDs and other emerging therapies to enhance outcomes in HR+/HER2- metastatic breast cancer.

EP. 1: Shifting Paradigms: Biomarker Testing and ESR1 Mutation Surveillance in HR+ HER2- Breast Cancer

January 15th 2025

Dr. Clifton and Dr. Gandhi discuss the critical role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer, and its impact on prognosis and treatment decision-making.